For over 40 years, the Switzerland based pharmaceutical and biotechnology company Helsinn has been committed to providing cutting edge treatments against cancer and other key diseases. Led by CEO Riccardo Braglia, the company maintains a worldwide presence and focus on innovative and quality products designed to help patients receive quality…

Lugano, Switzerland — Shanghai, China, October 12, 2021 — Helsinn Group (“Helsinn”), a Swiss Biopharmaceutical Group with an innovative R&D pipeline in cancer supportive care and oncology therapeutics, strategically investing in a fully integrated targeted therapy structure to develop, manufacture and commercialize small molecules in precision medicine with higher market…

LUGANO, Switzerland, and PALO ALTO, CA, September 29, 2021 — Helsinn Group and BridgeBio Pharma, Inc. (Nasdaq: BBIO), through its affiliate QED Therapeutics, Inc., today announced that Health Canada has approved TRUSELTIQ™ (infigratinib), a small molecule kinase inhibitor that targets fibroblast growth factor receptor (FGFR), under the Notice of Compliance…

People buy art to appreciate it and enhance their life and environment. Ancient Greek and Egyptian civilizations started collecting art, and the early art collectors used their pieces to reflect status and wealth. After the fall of Rome, the art market was relatively stagnant until the rebirth of the classical…

The chief executive officer and group vice chairman of the board of Helsinn Group in Lugano, Switzerland, Riccardo Braglia has spent 35 years as a professional in the healthcare industry, both as a business leader and philanthropist. He gained international experience in the pharmaceutical industry, which involved activities in Switzerland…